Tute Genomics Closes Additional Series A1 Funding With Strategic Investment From Intermountain Healthcare, Healthbox, and Tencent



PROVO, Utah, June 16, 2015 /PRNewswire/ — Tute Genomics, a leader in cloud-based analytics, interpretation, and reporting for clinical sequencing, today announced the closing of its Collection A1 round of venture capital funding. The company raised over $3.9 million from a strategic group of investors, including internationally recognized Intermountain Healthcare, an integrated network of 22 hospitals and 185 physician clinics. Various other major investors include Healthbox, a platform for innovation and entrepreneurship in healthcare, and China-based Tencent, one of the largest Internet companies in the world.



“Intermountain has actually gained a durable commitment to innovation and entrepreneurship within the healthcare system,” remarked Reid Robison, MD MBA, and CEO of Tute Genomics. “Intermountain’s target of providing much better Good health outcomes and a lot more affordable care corresponds perfectly along with our own quest to give rapid diagnoses, a lot more accurate treatments, and preventive medicine through genomics. Various other forward-looking healthcare organizations are certain to follow Intermountain’s lead, as tomorrow’s healthcare will certainly be steered by technological innovations.”


The victory of the most up to date investment round moves Tute Genomics closer to its target of bringing technology for genome-guided precision medicine to the masses.



“Tute Genomics has actually worked tirelessly to make clinical interpretation and reporting of genomic data accessible to healthcare providers, and global investors have actually taken notice,” mentioned Kai Wang, PhD, President and Chairman of Tute Genomics. “Previous investors in this Collection include Peak Ventures and UK-based Eurovestech. With each other along with our partners, we have actually the power to transform healthcare and improve the lives of millions of people.”



Healthbox and Tencent joined Intermountain Healthcare as strategic investors in this recent financing. Healthbox is an integrated innovation platform, enabling healthcare entrepreneurs to grow sustainable businesses and aiding leading healthcare organizations arrive internal innovation. Nina Nashif, founder and CEO of Healthbox, will certainly be joining the Tute Genomics Board on behalf of Intermountain Healthcare. Tencent is a leading provider of Internet services in China. It seeks to evolve along with the Internet by investing in innovation, providing a hospitable environment for partners, and staying close to users.



The genome revolution is here, and Tute envisions a future where genome sequencing is section of timetable clinical care, along with genomic data integrated in to medical records where it is most practical and actionable, giving doctors and patients alike access to genomic write-up at their fingertips. Genomics is changing healthcare as we know it, and along with this Brand-new support from strategic investment partners, Tute is well poised to suggestions shape the future of medicine: unlocking the genome, personalizing treatment, and accelerating discovery.



About Tute Genomics



Tute Genomics is a Utah-based company that is powering the world’s genomic knowledge along with a cloud-based genome interpretation platform for healthcare to allow predictive, preventive and precision medicine through genomics. To learn a lot more please visit www.tutegenomics.com and follow us on twitter @TuteGenomics.



About Intermountain Healthcare



Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group along with some 1,300 employed physicians, a Good health plans division called SelectHealth, and Various other Good health services. aiding people live the healthiest lives possible, Intermountain is widely recognized as a leader in transforming healthcare through higher quality and sustainable costs.  For a lot more write-up Regarding Intermountain, visit intermountainhealthcare.org, read our blogs at intermountainhealthcare.org/blogs, connect along with us on Twitter at twitter.com/intermountain and on Facebook at facebook.com/intermountain.



About Healthbox



Healthbox is the preeminent source of healthcare innovation and drives actionable collaboration between inventors, entrepreneurs and the healthcare industry. Our studio programs offer serious entrepreneurs the candid, unparalleled healthcare industry access and help required to gain in a complex marketplace. We additionally partner along with leading healthcare organizations to arrive a culture of pointer generation, business creation and external collaboration. along with operations in Boston, Chicago, Florida, Salt Lake City and London, Healthbox is building a strong, global community dedicated to driving adjustment in healthcare. Healthbox has actually a portfolio of a lot more compared to 75 energetic companies and strategic partnerships along with a lot more compared to 30 healthcare organizations. For a lot more information, visit www.healthbox.com.



About Tencent



Tencent uses technology to enrich the lives of Internet users. Every day, hundreds of millions of people communicate, share experiences, eat write-up and seek entertainment through our integrated platforms. Tencent’s diversified services include QQ, Weixin/ WeChat for communications; Qzone for social networking; QQ Game Platform for online games; QQ.com and Tencent News for write-up and Tencent Video for video content.



Tencent was founded in Shenzhen in 1998 and went public on the Main Board of the Hong Kong Stock Exchange in 2004. The Company is one of the constituent stocks of the Hang Seng Index.



Contact:



Josh Forsythe
858-779-4363 
Email





SOURCE Tute Genomics

Related Links


http://www.tutegenomics.com

PA Pavilion Champions Area Life Science Community at BIO International









PHILADELPHIA, June 15, 2015 /PRNewswire/ — Clarkston Consulting, a leading management and technology consulting firm specializing in the life science and consumer products industries, is honored to partner along with Pennsylvania Bio at the 201five BIO Global Convention.

The 201five BIO Global Convention takes position June 15-18 at the Philadelphia Convention Center. As the leading conference for the global biotechnology community, BIO Global offers educational sessions covering trending topics and ground-breaking science, day-to-day networking events, and the opportunity to fulfill along with a range of potential partners and investors. The conference agenda covers a range of topics, including:

  • Business Improvement & Finance
  • Corporate Finest Practices
  • Digital Good health
  • Emerging Opportunities in Global Markets
  • Intellectual Property
  • Next Generation Biotherapeutics
  • Orphan & Rare Diseases
  • Personalized Medicine & Diagnostics
  • Value, Patient Access, & Commercialization

As an suffered provider of consulting solutions and solutions for biotech, pharmaceutical and medical device companies, Clarkston Consulting is a proud sponsor of the Pennsylvania Pavilion at BIO International. Throughout the conference, Clarkston Consulting Partners will certainly be introducing a range of speakers on the PA Pavilion stage, which will certainly consist of presentations from several of Pennsylvania’s leading life science companies, universities and research institutions.  

“We are proud to support the Pennsylvania Pavilion at BIO Global this year,” said Clarkston Partner and Life Sciences Technique Leader Janel Firestein. “This is an opportunity for us to not just promote Pennsylvania as a hub for innovation within the life science industry, yet to likewise champ the numerous organizations that have actually helped the region grow and prosper.”

About Clarkston Consulting

Clarkston Consulting provides management and technology consulting solutions for life science and consumer products companies. Clarkston has actually accomplished a 12-year standard client satisfaction fee of 97% by regularly pushing for victory for our clients, our consultants, and our company. For a lot more information, please visit www.clarkstonconsulting.com.

About Pennsylvania Bio

Pennsylvania Bio is the statewide trade association for the life sciences in Pennsylvania and serves as a catalyst to make sure Pennsylvania is a global leader in the life sciences by making a Firm and public policy environment which fosters life science growth and success. a lot more short article is available at http://www.pabio.org.

About BIO Global Convention

The largest, the majority of influential biotech meeting on the planet is coming to Philadelphia, June 15-18, 2015, offering powerful Firm partnering, invaluable education sessions and networking along with the industry’s Finest and brightest. Join the global biotech community at BIO 201five and fuel the extraordinary. Register now at convention.bio.org.

Contact: Jessica Eure | jeure@clarkstonconsulting.com | 919-484-4445

Logo – http://photos.prnewswire.com/prnh/20141229/166242LOGO

 

SOURCE Clarkston Consulting

RELATED LINKS
http://www.clarkstonconsulting.com

Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark




























DARMSTADT, Germany, June 14, 2015 /PRNewswire/ —

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that the 2 innovative fertility technologies Gavi and Geri have actually cleared a serious milestone, achieving CE Mark certification. Merck KGaA, Darmstadt, Germany, recently signed a global collaboration agreement along with Genea Biomedx, the manufacturer of the two products. along with this partnership, Merck KGaA, Darmstadt, Germany, received global marketing and commercialization rights to Genea Biomedx’s product portfolio. All of products will certainly be offered through Merck KGaA, Darmstadt, Germany’s Fertility Technologies unit.

     (Logo: http://photos.prnewswire.com/prnh/20150608/748423-a )

     (Logo: http://photos.prnewswire.com/prnh/20150608/748423-b )

The achievement of regulatory clearance allows Gavi and Geri to be gained available for sale in the European Union.

Conceived through the fertility knowhow of Genea Biomedx’s moms and dad company Genea, the instruments are made to give solutions to a few of the challenges involved in successful fertility treatment:

Gavi is the world’s very first automated vitrification instrument which uses an automated, standardized protocol aiming to guarantee consistent outcomes in blastocyst vitrification. Geri is a benchtop incubator that involves a camera system that allows scientists to view the embryo devoid of repeatedly removing it from its optimal environment.

Gavi and Geri will certainly be on display and available to order at ESHRE in Portugal 14-17 June 2015.

Genea Biomedx  

Genea Biomedx creates and manufactures practical, accessible and precise fertility technologies that insight standardise and automate fertility treatment. Its unique partnership along with Genea Fertility means that Genea Biomedx is a manufacturer that actually understands the customers’ perspective. As a result Genea Biomedx has actually created the world’s very first automated vitrification instrument, and has actually various other projects well advanced in the product pipeline.  

Gavi and Geri  

  • Gavi – the world’s very first automated vitrification instrument; Vitrification is a process used in IVF to sustain human egg cells (oocytes) or embryos by cooling them to deep sub-zero degrees. Approaching the process in an innovative way, Gavi uses an automated, standardized protocol aiming to give consistent outcomes in blastocyst vitrification.
  • Geri – a benchtop incubator along with individually controlled incubation chambers per patient to minimize disruptive events to the early-stage embryo. It additionally incorporates a camera system to capture images of embryos as they develop.

About Merck KGaA, Darmstadt, Germany, and its biopharmaceutical business 

Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has actually 6 businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance contents – and generated sales of € 11.3 billion in 2014. About 39,000 employees job in 66 countries to increase the quality of life for patients, to foster the victory of customers and to insight meet global challenges. Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company – due to the fact that 1668, the company has actually stood for innovation, business victory and responsible entrepreneurship. Holding an around 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

With headquarters in Darmstadt, Germany, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, offers leading brands in 150 countries to insight patients along with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders too as cardio diseases.

The biopharmaceutical business of Merck KGaA, Darmstadt, Germany, discovers, develops, manufactures and markets prescription medicines of the two chemical and biological origin in specialist indications. We have actually an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

SOURCE Merck KGaA

Optimizing the Mix of Market Research Activities in the Pharmaceutical Industry to Provide Value to Internal Leaders






CHAPEL HILL, N.C., June 12, 2015 /PRNewswire/ — Market research teams within the pharmaceutical sector frequently rely on the two tracking research and suggestions research projects to inform brand and others functional leaders within their organization. Various functional teams within biopharmaceutical companies utilize these research approaches to guide their strategies for increasing top-line growth also as market position.

To guarantee market research teams satisfy their numerous obligations, leaders have to guarantee they effectively train market research staff, already know internal clients’ needs, and realize the weaknesses of Various research types. Ideal Practices, LLC conducted a primary research study to provide market research leaders insights in to the practices, mix, staffing, and activity levels called for to consistently offer valuable, forward-looking market research insights in to the business.

Specifically, this study examines the optimal mix of suggestions to tracking research, the allocation of budget and staffing resources for Various types of projects, and the management and prioritization of ad-hoc versus planned research assignments. The research entails an assessment of pitfalls for presenting tracking and suggestions research, training approaches for market research staff and efficient means to communicate along with internal clients to guarantee the value of research is conveyed.

The study, “Forging Deep Insights to Grow the Business: Exactly how Market Research Organizations Optimize the Mix of Tracking Research and Insight-Oriented Research,” found that projects conducted as ad-hoc requests vs. projects that are planned beforehand is a sensitive subject among market research leaders. The useful dilemma: market research complains as well considerably job is conducted as ad-hoc requests; however, marketing colleagues contend ad hoc requests reflect the dynamic nature of the marketplace and competition.

The depth of insights in the study extends across the crucial aspects of producing and preserving an efficient market research group and include:

  • Ideal mix of tracking vs. suggestions research
  • Overall relative impact of tracking and suggestions research projects
  • Impact of projects based on lifecycle stage of product
  • Improving the impact of the two tracking and suggestions research projects
  • Removing redundancy of projects across brands/therapeutic areas
  • Allocation of budget and staffing resources for Various types of projects
  • Managing and prioritizing ad-hoc vs. planned research assignments
  • Winning trust and track record internally
  • Training for successful communication and implementation of insights

Best Practices, LLC engaged 14 Market Research leaders through a targeted benchmark survey instrument.

To learn a lot more concerning this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1357.htm.

For related research, visit our Ideal Practices, LLC Web site at http://www.best-in-class.com .

ABOUT Ideal PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Ideal Practices, LLC’s clients contain all of the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

SOURCE Ideal Practices, LLC

RELATED LINKS
http://www.best-in-class.com

Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis






VIENNA, June 12, 2015 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International’s BioScience business (NYSE: BAX) today announced Brand-new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor along with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently reported at the American Society of Clinical Oncology (ASCO) annual meeting, results prove to a substantial reduction in the Total Symptom Score (TSS) (the proportion of patients along with a 50 percent or higher reduction in TSS from baseline to Week 24), and in each specific common disease-related symptom, from baseline to Week 24, in patients treated along with pacritinib compared to ideal available therapy (exclusive of a JAK inhibitor) (BAT). These PROs, as well as others quality of life measures, will certainly be presented at the 20th Congress of European Hematology Association (EHA) by Adam Mead, M.D., Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom in an oral presentation on Sunday, June 14, 2015 at 12:15 CEST (abstract #LB2072). These data were likewise picked for inclusion in the official EHA Press Briefing which occurred today (Friday, June 12, 2015) at 08:30 CEST. As previously reported, the PERSIST-1 trial met its primary endpoint of spleen volume reduction of 35 percent or higher from baseline to Week 24 as measured by MRI/CT scan.

Myelofibrosis is a rare blood cancer associated along with significantly reasonable quality of life and shortened survival. As the disease progresses, the physique slows production of essential blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (quite reasonable blood platelet counts), severe anemia, and red blood cell transfusion requirements boosts significantly. Among others complications, most patients along with myelofibrosis present along with enlarged spleens (splenomegaly), as well as lots of others potentially devastating physical symptoms such as abdominal discomfort, bone pain, feeling full after consuming little, severe itching, night sweats, and extreme fatigue.

“Patient-reported outcomes are an essential measure for understanding the potential benefit of a therapy on patients’ lives – particularly for a disease such as myelofibrosis where the symptoms have actually such a tremendous impact on the quality of patients’ day-to-day lives,” stated James A. Bianco, M.D., President and CEO of CTI BioPharma. “These Brand-new data from the PERSIST-1 study further support our belief, not only in the activity of pacritinib, however likewise the potential to positively impact patients’ day-to-day lives by relieving the symptoms that accompany myelofibrosis.” 

“The PERSIST-1 trial has actually continued to generate positive and essential findings for the hematology community,” said David Meek, Head of Oncology at Baxter BioScience. “We look forward to advancing the clinical trial program of pacritinib as we job to realize the full potential of this investigational compound to advice patients along with serious blood cancers, such as myelofibrosis.”

Study Details and Findings Presented at EHA
PERSIST-1 is a randomized (2:1), controlled Phase 3 registration-directed trial comparing the efficacy and safety of pacritinib to BAT – which included a range of currently utilized off-label treatments – in 327 patients along with myelofibrosis, regardless of the patients’ platelet counts. As previously reported at ASCO, the trial met its primary endpoint of spleen volume reduction (35 percent or higher reduction from baseline to Week 24 by MRI/CT scan) in the intent-to-treat (ITT) population; these results included patients along with severe or life-threatening thrombocytopenia. The study likewise measured patient-reported outcomes (PROs), the proportion of patients along with a 50 percent or higher reduction in TSS from baseline to Week 24, which have actually become essential for approval of Brand-new therapies and was one of the secondary endpoints of the study. As previously reported, patients treated along with pacritinib suffered higher improvement in their disease-related symptoms (ITT patient population: 24.5 percent of pacritinib-treated patients vs 6.5 percent of BAT-treated patients, p<0.0001; evaluable patient population: 40.9 percent of pacritinib-treated patients vs 9.9 percent of BAT-treated patients, p<0.0001).

New data presented at EHA, which included results from multiple PROs measurement tools, showed:

Myeloproliferative Neoplasm Symptom Assessment (MPN-SAF TSS and MPN-SAF TSS 2.0)
As quickly as using the MPN-SAF TSS and MPN-SAF TSS 2.0, each of the 6 common disease-related symptoms from the TSS results showed improvements in abdominal discomfort (46 percent improvement along with pacritinib vs no improvement along with BAT); bone pain (32 percent improvement along with pacritinib vs 8 percent improvement along with BAT); feeling of early fullness (45 percent improvement along with pacritinib vs 1 percent worsening along with BAT); itching (48.5 percent improvement along with pacritinib vs 10 percent improvement along with BAT); night sweats (69.5 percent improvement along with pacritinib vs no improvement along with BAT); and fatigue (27.5 percent improvement along with pacritinib vs 4 percent worsening along with BAT). MPN-SAF TSS and MPN-SAF TSS 2.0 are individual sets of questions patients answer day-to-day (via electronic diary) and which are based on a questionnaire originally created by Ruben A. Mesa, M.D., Deputy Director of the Mayo Clinic Cancer Focus in Scottsdale, Arizona, USA.

Patient Global Impression of Modification (PGIC)
Based on the PGIC assessment – which measures a patient’s assessment of overall health on a 7-point scale ranging from “quite much worse” to “quite much improved” – approximately 80 percent of evaluable patients treated along with pacritinib rated their condition as improved compared to approximately 20 percent along with BAT.

European Organization for Research and Treatment of Cancer Quality-of-Life 30 Questionnaire (EORTC QLQ-C30)
A higher improvement was likewise reported by evaluable patients treated along with pacritinib vs BAT across all components of the EORTC QLQ-C30 questionnaire, a well-validated measure of quality of life in cancer patients.

The most common edge events occurring along with pacritinib within 24 weeks, of any grade, were mild to moderate diarrhea (53.2 percent vs 12.3 percent along with BAT), nausea (26.8 percent vs 6.6 percent along with BAT), anemia (22.3 percent vs 19.8 percent along with BAT), thrombocytopenia (16.8 percent vs 13.2 percent along with BAT), and vomiting (15.9 percent vs 5.7 percent along with BAT). Of the patients treated along with pacritinib, 3 discontinued therapy and 13 patients needed dose interruption (standard one week) for diarrhea. Patients received a day-to-day full dose of pacritinib over the duration of treatment. Gastrointestinal symptoms typically lasted for approximately one week and few patients discontinued treatment as a result of adverse effects. There were no Grade 4 gastrointestinal events reported.

About Pacritinib
Pacritinib is an investigational oral multikinase inhibitor along with specificity for JAK2 and FLT3. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have actually been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma.

About Myelofibrosis
Myelofibrosis is a serious and life-threatening chronic blood cancer caused by the accumulation of malignant bone marrow cells that causes an inflammatory response and scars the bone marrow. The replacement of bone marrow along with scar tissue limits its ability to develop red blood cells, prompting the spleen and liver to take over this function. Symptoms that arise from this disease include enlargement of the spleen, anemia, extreme fatigue, and pain.  Myelofibrosis is a one of three main types of myeloproliferative neoplasms (MPN), which are a closely related group of hematological blood cancers.1 The estimated prevalence of MPNs suggest there are approximately 300,000 individuals living along with the disease in the U.S. of which myelofibrosis accounts for approximately 18,000 patients.2 In Europe, there is a wide variation of prevalence observed across data sources. Myelofibrosis has actually a median age of 64 at the time of diagnosis2 and is a progressive disease along with approximately 20 percent of patients eventually making acute myeloid leukemia.3 The median survival for high-risk patients is much less compared to one and a half years; median survival for myelofibrosis patients overall is approximately 6 years.4

About the PERSIST Phase 3 Development Program of Pacritinib
Pacritinib is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients along with myelofibrosis. PERSIST-1 is a randomized (2:1), open-label, multinational Phase 3 clinical trial comparing the efficacy and safety of pacritinib along with that of BAT, in 327 enrolled patients along with primary and secondary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-necessary thrombocythemia myelofibrosis (PET-MF), devoid of exclusion for reasonable platelet counts. PERSIST-2 is a randomized (2:1), open-label, multinational Phase 3 clinical trial evaluating pacritinib compared to BAT, including the approved JAK1/JAK2 inhibitor dosed according to product label for patients along with myelofibrosis whose platelet counts are much less compared to or equal to 100,000 per microliter. The trial is designed to enroll up to 300 patients in North America, Europe, Australia, New Zealand, and Russia.

Additional details are available at www.clinicaltrials.gov or www.PERSISTprogram.com.

CTI BioPharma and Baxter BioScience, which is expected to become Baxalta Incorporated in mid-2015, entered in to a global license agreement in November 2013 to produce and commercialize pacritinib. CTI BioPharma and Baxter will certainly jointly commercialize pacritinib in the U.S. while Baxter has actually exclusive commercialization rights for all indications outside the U.S.

About CTI BioPharma Corp.
CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has actually a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients along with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, along with offices in London and Milan under the name CTI Life Sciences Limited. For additional article and to sign up for email alerts and grab RSS feeds, please visit www.ctibiopharma.com.

About Baxter Global Inc.
Baxter Global Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of individuals along with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and others chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to produce products that advance patient care worldwide.

Forward Looking Statements
This press release includes forward-looking statements related to pacritinib and related clinical trials conducted pursuant to a collaboration between Baxter Global Inc. and CTI BioPharma Corp., as well as statements concerning the planned separation of Baxter’s biopharmaceutical and medical products businesses, which are within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the issuers’ securities. Such statements include, however are not limited to, statements concerning expectations along with respect to the potential therapeutic utility of pacritinib, the ability of the PERSIST-1 and PERSIST-2 trials to support a potential regulatory submission, the anticipated completion of enrollment, the ability of pacritinib to meet unmet medical requires and future regulatory, development and commercialization plans. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and are based on assumptions Concerning lots of essential factors and article currently available to us to the extent we have actually thus far had an opportunity to evaluate such article in light of all surrounding facts, circumstances, guidance and analyses. A number of results and uncertainties could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and others requirements; clinical trial results; changes in laws and regulations; product quality, product efficacy, study protocol, data integrity or patient safety issues; product development risks; and others risks identified in each issuer’s most recent filings on Form 10-K and others Securities and Exchange Commission filings as well as the Form 10 filed by Baxalta Incorporated. Neither Baxter nor CTI BioPharma undertakes to update its forward-looking statements.

1. MPN Research Foundation website, www.mpnresearchfoundation.org.

2. Based on Mesa R, ASH 2012 poster.

3. Cervantes F, et al., Brand-new prognostic scoring system for primary myelofibrosis based on a study of the Global Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113:2895-2901.

4. Vannucchi, A. Management of Myelofibrosis. ASH Education Book. 2011; 1:222-230.

CTI BioPharma Contact:
Monique Greer
206-272-4343
mgreer@ctibiopharma.com

Baxter Investor Contact:
Mary Kay Ladone
224-948-3371

Baxter Media Contact:
Kellie Hotz
224-948-5353
media@baxter.com

 

SOURCE CTI BioPharma Corp.; Baxter

RELATED LINKS
http://www.ctibiopharma.com